Immunic, Inc. (NASDAQ:IMUX) Director Richard Alan Rudick Purchases 87,300 Shares of Stock

Immunic, Inc. (NASDAQ:IMUX) Director Richard Alan Rudick purchased 87,300 shares of the stock in a transaction dated Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the acquisition, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Immunic Price Performance

NASDAQ:IMUX opened at $1.17 on Thursday. Immunic, Inc. has a one year low of $0.97 and a one year high of $2.11. The company’s 50-day simple moving average is $1.45 and its 200 day simple moving average is $1.35. The firm has a market capitalization of $105.39 million, a P/E ratio of -0.95 and a beta of 1.88.

Institutional Investors Weigh In On Immunic

A number of institutional investors have recently modified their holdings of IMUX. Vanguard Group Inc. boosted its stake in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. Janus Henderson Group PLC purchased a new position in Immunic in the first quarter worth about $9,266,000. Ikarian Capital LLC lifted its stake in shares of Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Immunic during the first quarter valued at approximately $25,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on IMUX shares. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research note on Monday. B. Riley started coverage on Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price target on the stock. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research note on Monday, September 16th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $11.20.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.